EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study

Marianna Stasinopoulou iD, Nikolaos Kostomitsopoulos iD, Nikolaos P E Kadoglou iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25126614 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Marianna Stasinopoulou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Center of Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece. Hauptthemen laut MEDLINE: Bosentan, Atorvastatin, Atherosclerosis, Endothelin Receptor Antagonists. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Bosentan, an endothelin receptor antagonist (ERA), has potential anti-atherosclerotic properties. We investigated the complementary effects of bosentan and atorvastatin on the progression and composition of the atherosclerotic lesions in diabetic mice. Forty-eight male ApoE−/− mice were fed high-fat diet (HFD) for 14 weeks. At week 8, diabetes was induced with streptozotocin, and mice were randomized into four groups: (1) control/COG: no intervention; (2) ΒOG: bosentan 100 mg/kg/day per os; (3) ATG: atorvastatin 20 mg/kg/day per os; and (4) BO + ATG: combined administration of bosentan and atorvastatin. The intra-plaque contents of collagen, elastin, monocyte chemoattractant protein-1 (MCP-1), tumor necrosis factor-a (TNF-a), matrix metalloproteinases (MMP-2, -3, -9), and TIMP-1 were determined. The percentage of lumen stenosis was significantly lower across all treated groups: BOG: 19.5 ± 2.2%, ATG: 12.8 ± 4.8%, and BO + ATG: 9.1 ± 2.7% compared to controls (24.6 ± 4.8%, p < 0.001). The administration of both atorvastatin and bosentan resulted in significantly higher collagen content and thicker fibrous cap versus COG (p < 0.01). All intervention groups showed lower relative intra-plaque concentrations of MCP-1, MMP-3, and MMP-9 and a higher TIMP-1concentration compared to COG (p < 0.001). Importantly, latter parameters presented lower levels when bosentan was combined with atorvastatin compared to COG (p < 0.05). Bosentan treatment in diabetic, atherosclerotic ApoE−/− mice delayed the atherosclerosis progression and enhanced plaques’ stability, showing modest but additive effects with atorvastatin, which are promising in atherosclerotic cardiovascular diseases.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BosentanAtorvastatinAtherosclerosisEndothelin Receptor AntagonistsAnimalsMiceMaleDiabetes Mellitus, ExperimentalDrug Therapy, CombinationCollagenDiet, High-FatChemokine CCL2Tumor Necrosis Factor-alphaPlaque, AtheroscleroticMice, KnockoutTissue Inhibitor of Metalloproteinase-1

Stichwörter der Autor:innen

atherosclerosisatorvastatinbosentanendothelin receptor antagonist (ERA)matrix metalloproteinasesplaque stability

Substanzen

BosentanAtorvastatinEndothelin Receptor AntagonistsCollagenChemokine CCL2Tumor Necrosis Factor-alphaTissue Inhibitor of Metalloproteinase-1

Autor:innen und Institutionen

  • Center of Clinical, Experimental Surgery, and Translational Research, Biomedical Research Foundation, Academy of Athens, 115 27 Athens, Greece.
  • Medical School, University of Cyprus, 2029 Nicosia, Cyprus.

ORCID-Profile: Marianna Stasinopoulou, Nikolaos Kostomitsopoulos, Nikolaos P E Kadoglou

Zitieren

APA

Stasinopoulou, M., Kostomitsopoulos, N., & Kadoglou, N. P. E. (2024). The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25126614

Vancouver

Stasinopoulou M, Kostomitsopoulos N, Kadoglou NPE. The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25126614

BibTeX
@article{Stasinopoulou2024,
  author = {Stasinopoulou, Marianna and Kostomitsopoulos, Nikolaos and Kadoglou, Nikolaos P E},
  title = {The Anti-Atherosclerotic Effects of Endothelin Receptor Antagonist, Bosentan, in Combination with Atorvastatin—An Experimental Study},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25126614}
}
Kostenlos starten →